LEPU BIO (02157) shares climbed nearly 4% in early trading, briefly surging over 12%. As of press time, the stock was up 3.83% at HK$4.61, with turnover reaching HK$91.6484 million.

On July 28, the company announced an update on its collaboration with AstraZeneca AB, a global biopharmaceutical firm, regarding the antibody-drug conjugate (ADC) candidate CMG901 (sonesitatug vedotin, also known as AZD0901).

In February 2023, KYM Biosciences Inc. (KYM), a joint venture established by the company and Konos Biopharma, entered into a global exclusive license agreement with AstraZeneca to develop and commercialize CMG901. As of the announcement date, positive topline results from the global Phase III CLARITY-Gastric01 trial showed that sonesitatug vedotin demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to the investigator's choice of treatment in patients with 2L+ Claudin 18.2-positive advanced gastric cancer.